| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1200/JCO.2005.07.501 |
| P698 | PubMed publication ID | 16192605 |
| P50 | author | Mitch Dowsett | Q53099690 |
| P2093 | author name string | Ian E Smith | |
| Ander Urruticoechea | |||
| P433 | issue | 28 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast cancer | Q128581 |
| P304 | page(s) | 7212-7220 | |
| P577 | publication date | 2005-10-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Proliferation marker Ki-67 in early breast cancer | |
| P478 | volume | 23 |
| Q57812161 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) Induces Peripheral Blood Abnormalities and Plasma Cell Neoplasms Resembling Multiple Myeloma in Mice |
| Q51106107 | A High Ki67/BCL2 Index Could Predict Lower Disease-Free and Overall Survival in Intestinal-Type Gastric Cancer. |
| Q38920080 | A Raman spectroscopic study of cell response to clinical doses of ionizing radiation. |
| Q44327149 | A clinicopathological analysis of primary mucosal malignant melanoma |
| Q47986847 | A comparative study of Ki-67 antigen expression between luminal A and triple-negative subtypes of breast cancer |
| Q37520194 | A comparison of R-EPOCH and R-CHOP as a first-line regimen in de novo DLBCL patients with high Ki-67 expression in a single institution |
| Q51247871 | A discrimination index for selecting markers of tumor growth dynamic across multiple cancer studies with a cure fraction. |
| Q50853316 | A new Ki-67 / E-cadherin cocktail reduces inter-observer variation of the calculated proliferative index. |
| Q33801255 | A novel model for Ki67 assessment in breast cancer |
| Q84902561 | A pre-tailored panel of antibodies in the study of cervical mesonephric remnants |
| Q37411858 | A proteomic adaptation of small intestinal mucosa in response to dietary protein limitation |
| Q27335560 | A quantitative microfluidic angiogenesis screen for studying anti-angiogenic therapeutic drugs. |
| Q42492946 | A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments |
| Q36507085 | A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer |
| Q38555389 | A survey of state-of-the-art surface chemistries to minimize fouling from human and animal biofluids |
| Q35547522 | ACE-inhibition increases podocyte number in experimental glomerular disease independent of proliferation |
| Q37419375 | ADA3 regulates normal and tumor mammary epithelial cell proliferation through c-MYC. |
| Q39357739 | AKR1B10 overexpression in breast cancer: association with tumor size, lymph node metastasis and patient survival and its potential as a novel serum marker |
| Q36105958 | ALK alteration is a frequent event in aggressive breast cancers. |
| Q39082461 | AQP5 expression predicts survival in patients with early breast cancer |
| Q91168620 | ATF3 and JDP2 deficiency in cancer associated fibroblasts promotes tumor growth via SDF-1 transcription |
| Q34373013 | ATG4B promotes colorectal cancer growth independent of autophagic flux. |
| Q43280771 | Abemaciclib: First Global Approval |
| Q92445590 | Adipose-Derived Mesenchymal Stem Cells Isolated from Patients with Type 2 Diabetes Show Reduced "Stemness" through an Altered Secretome Profile, Impaired Anti-Oxidative Protection, and Mitochondrial Dynamics Deterioration |
| Q88682212 | Aldolase A promotes proliferation and G1/S transition via the EGFR/MAPK pathway in non-small cell lung cancer |
| Q36956220 | An associated classification of triple negative breast cancer: the risk of relapse and the response to chemotherapy |
| Q37463125 | An international Ki67 reproducibility study |
| Q38464311 | Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer. |
| Q38861446 | Anti-proliferative effects of γ-tocotrienol are associated with suppression of c-Myc expression in mammary tumour cells |
| Q96576723 | Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer |
| Q53076800 | Apparent diffusion coefficient as a potential surrogate marker for Ki-67 index in mucinous breast carcinoma. |
| Q37708928 | Application of pharmacologically induced transcriptomic profiles to interrogate PI3K-Akt-mTOR pathway activity associated with cancer patient prognosis |
| Q36675384 | Aromatase inhibitors in early breast cancer therapy: a variety of treatment strategies |
| Q64892623 | Assessment of Ki-67 as a potential biomarker in patients with breast cancer. |
| Q40089766 | Assessment of Ki67 expression for breast cancer subtype classification and prognosis in the Nurses' Health Study. |
| Q35552069 | Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group |
| Q47923765 | Assessment of the Cancer Risk of the Fat-Grafted Breast in a Murine Model |
| Q50690348 | Assessment of the Ki67 labeling index: a Japanese validation ring study. |
| Q28483692 | Astemizole synergizes calcitriol antiproliferative activity by inhibiting CYP24A1 and upregulating VDR: a novel approach for breast cancer therapy |
| Q36001510 | Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer |
| Q53627332 | Bcl2 and Ki67 refine prognostication in luminal breast cancers. |
| Q35737313 | Bi-phasic expression of Heterochromatin Protein 1 (HP1) during breast cancer progression: Potential roles of HP1 and chromatin structure in tumorigenesis |
| Q36295142 | Biomarkers in Breast Cancer - An Update |
| Q38052925 | Biomarkers in the diagnosis of primary and recurrent breast cancer |
| Q26775094 | Biomarkers in triple negative breast cancer: A review |
| Q24602679 | Breast Cancer in the Personal Genomics Era |
| Q37803121 | Breast cancer assessment tools and optimizing adjuvant therapy. |
| Q29006708 | Breast cancer pathology, receptor status, and patterns of metastasis in a rural Appalachian population |
| Q58725493 | Breast cancer risk factors, survival and recurrence, and tumor molecular subtype: analysis of 3012 women from an indigenous Asian population |
| Q50631240 | Brief fixation does not hamper the reliability of Ki67 analysis in breast cancer core-needle biopsies: a double-centre study. |
| Q36830014 | Cell Proliferation (KI-67) Expression Is Associated with Poorer Prognosis in Nigerian Compared to British Breast Cancer Women |
| Q33626612 | Cells of renin lineage take on a podocyte phenotype in aging nephropathy |
| Q36765407 | Cellular metabolic energy modulation by tangeretin in 7,12-dimethylbenz(a) anthracene-induced breast cancer |
| Q36245350 | Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer |
| Q35903324 | Chemically modified peptides targeting the PDZ domain of GIPC as a therapeutic approach for cancer |
| Q33699104 | Chromatin CKAP2, a new proliferation marker, as independent prognostic indicator in breast cancer |
| Q38199995 | Chromatin dynamics: H3K4 methylation and H3 variant replacement during development and in cancer. |
| Q33942256 | Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemia |
| Q42790681 | Circulating Ki-67 protein in plasma as a biomarker and prognostic indicator of acute lymphoblastic leukemia |
| Q34315684 | Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. |
| Q39612713 | Classical markers like ER and ki-67, but also survivin and pERK, could be involved in the pathological response to gemcitabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients: results from the GEICAM/2002-01 phase II stud |
| Q51733186 | Clinical and economic impact of the 21-gene recurrence score assay in adjuvant therapy decision making in patients with early-stage breast cancer: pooled analysis in 4 Basque Country university hospitals. |
| Q35042063 | Clinical and histopathological factors associated with Ki-67 expression in breast cancer patients |
| Q64278930 | Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China |
| Q64078589 | Clinical impact of a cytological screening system using cyclin D1 immunostaining and genomic analysis for the diagnosis of thyroid nodules |
| Q64237850 | Clinical validation of Ki67 by quantitative reverse transcription-polymerase chain reaction (RT-PCR) in HR+/HER2- early breast cancer |
| Q40708757 | Clinicopathological Significance of the Proliferation Markers Ki67, RacGAP1, and Topoisomerase 2 Alpha in Breast Cancer |
| Q50655660 | Clinicopathological and prognostic significance of Ki-67 immunohistochemical expression of distant metastatic lesions in patients with metastatic breast cancer. |
| Q37641078 | Collagen gel droplet-embedded culture-drug sensitivity test and Ki67 expression in estrogen receptor-positive and HER2-negative breast cancer |
| Q39096429 | Combined γ-tocotrienol and Met inhibitor treatment suppresses mammary cancer cell proliferation, epithelial-to-mesenchymal transition and migration |
| Q84617448 | Comparative validation of the SP6 antibody to Ki67 in breast cancer |
| Q35681966 | Comparison of visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer |
| Q88792280 | Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers |
| Q54940119 | Conventional Pathology Versus Gene Signatures for Assessing Luminal A and B Type Breast Cancers: Results of a Prospective Cohort Study. |
| Q92648940 | Conversion of immunohistochemical markers and breast density are associated with pathological response and prognosis in very young breast cancer patients who fail to achieve a pathological complete response after neoadjuvant chemotherapy |
| Q57156396 | Copy number profiling of Oncotype DX genes reveals association with survival of breast cancer patients |
| Q38426713 | Correlation between (18)F-FDG uptake on PET/CT and prognostic factors in triple-negative breast cancer |
| Q38077896 | Correlation between Ki67 and breast cancer prognosis |
| Q92617708 | Correlation between procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 and breast cancer |
| Q42373819 | Crizotinib, a MET inhibitor, inhibits growth, migration, and invasion of breast cancer cells in vitro and synergizes with chemotherapeutic agents |
| Q28074202 | Current advances in biomarkers for targeted therapy in triple-negative breast cancer |
| Q33736774 | Cytoplasmic expression of the JM403 antigen GlcA-GlcNH3+ on heparan sulfate glycosaminoglycan in mammary carcinomas--a novel proliferative biomarker for breast cancers with high malignancy. |
| Q92316358 | Cytotoxic and Antiproliferative Effects of Preussin, a Hydroxypyrrolidine Derivative from the Marine Sponge-Associated Fungus Aspergillus candidus KUFA 0062, in a Panel of Breast Cancer Cell Lines and Using 2D and 3D Cultures |
| Q47270135 | DCE-MRI texture analysis with tumor subregion partitioning for predicting Ki-67 status of estrogen receptor-positive breast cancers. |
| Q90357707 | Decrease in the Ki67 index during neoadjuvant chemotherapy predicts favorable relapse-free survival in patients with locally advanced breast cancer |
| Q37649660 | Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-кB target genes in human breast cancer |
| Q90703470 | Depletion of mitochondrial protease OMA1 alters proliferative properties and promotes metastatic growth of breast cancer cells |
| Q44101885 | Deregulation of base excision repair gene expression and enhanced proliferation in head and neck squamous cell carcinoma |
| Q37160326 | Determination of GP88 (progranulin) expression in breast tumor biopsies improves the risk predictive value of the Nottingham Prognostic Index |
| Q38726645 | Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer. |
| Q54481769 | Developments in Ki67 and other biomarkers for treatment decision making in breast cancer. |
| Q40195184 | Different methods of pretreatment Ki-67 labeling index evaluation in core biopsies of breast cancer patients treated with neoadjuvant chemotherapy and their relation to response to therapy |
| Q43430523 | Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer |
| Q55403730 | Digital gene expression profiling analysis and its application in the identification of genes associated with improved response to neoadjuvant chemotherapy in breast cancer. |
| Q45911428 | Double inversion recovery MR imaging of the breast: efficacy in detection of breast cancer. |
| Q55512823 | Downregulation of aquaporin 3 inhibits cellular proliferation, migration and invasion in the MDA-MB-231 breast cancer cell line. |
| Q39676450 | Dynamic contrast-enhanced and diffusion-weighted MRI of estrogen receptor-positive invasive breast cancers: Associations between quantitative MR parameters and Ki-67 proliferation status |
| Q94591488 | Effect of Ki-67 Expression Levels and Histological Grade on Breast Cancer Early Relapse in Patients with Different Immunohistochemical-based Subtypes |
| Q34427448 | Effect of PREDICT on chemotherapy/trastuzumab recommendations in HER2-positive patients with early-stage breast cancer |
| Q46239843 | Effect of Vitamin D Supplementation on Breast Cancer Biomarkers: CALGB 70806 (Alliance) Study Design and Baseline Data |
| Q38400351 | Effect of bronchodilators on bronchial gland cell proliferation after inhalation and burn injury in sheep |
| Q38758139 | Effects of ginseng saponins isolated from Red Ginseng roots on burn wound healing in mice |
| Q36380822 | Embryonic morphogen nodal promotes breast cancer growth and progression |
| Q36386322 | Endocrine resistance in breast cancer--An overview and update |
| Q92332465 | Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence |
| Q83823143 | Endothelium-coated tumor clusters are associated with poor prognosis and micrometastasis of hepatocellular carcinoma after resection |
| Q42496058 | EpCAM expression is an indicator of recurrence in basal-like breast cancer |
| Q57116856 | Establishment and Characterization of gc-006-03, a Novel Human Signet Ring Cell Gastric Cancer Cell Line Derived from Metastatic Ascites |
| Q51766497 | Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation. |
| Q33750115 | Evaluation of FLT-PET-CT as an imaging biomarker of proliferation in primary breast cancer. |
| Q35979379 | Exometabolom analysis of breast cancer cell lines: Metabolic signature |
| Q89338547 | Expression of Gastric Markers Is Associated with Malignant Potential of Nonampullary Duodenal Adenocarcinoma |
| Q92645437 | Expression of Tim-3 in breast cancer tissue promotes tumor progression |
| Q46945863 | Expression of heparanase is associated with breed-specific morphological characters of placental folded bilayer between Yorkshire and Meishan pigs |
| Q80217907 | Expression signatures that correlated with Gleason score and relapse in prostate cancer |
| Q36482896 | Fatty acid binding protein 4 expression marks a population of adipocyte progenitors in white and brown adipose tissues |
| Q41045089 | Functional role of laminin α1 chain during cerebellum development |
| Q35543454 | GATA6 reporter gene reveals myocardial phenotypic heterogeneity that is related to variations in gap junction coupling. |
| Q57117421 | Genomic Testing in the Management of Early-Stage Breast Cancer |
| Q35175294 | HP1β is a biomarker for breast cancer prognosis and PARP inhibitor therapy |
| Q38710164 | HR+HER2- breast cancers with growth factor receptor-mediated EMT have a poor prognosis and lapatinib downregulates EMT in MCF-7 cells |
| Q38414170 | High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer. |
| Q39165155 | High MRI performance fluorescent mesoporous silica-coated magnetic nanoparticles for tracking neural progenitor cells in an ischemic mouse model |
| Q37121271 | High-throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association Consortium |
| Q36587555 | Histological grading of breast cancer on needle core biopsy: the role of immunohistochemical assessment of proliferation |
| Q38413575 | Histopathological subclassification of triple negative breast cancer using prognostic scoring system: five variables as candidates |
| Q28729183 | How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists |
| Q35763597 | Human tumor cell proliferation evaluated using manganese-enhanced MRI. |
| Q45810851 | IGF-1-mediated osteoblastic niche expansion enhances long-term hematopoietic stem cell engraftment after murine bone marrow transplantation. |
| Q33368855 | Identification of a gene signature in cell cycle pathway for breast cancer prognosis using gene expression profiling data |
| Q46376165 | Immunohistochemical characterisation of breast cancer: towards a new clasification? |
| Q79968177 | Immunohistochemical expression of heparan sulfate correlates with stromal cell proliferation in breast phyllodes tumors |
| Q98467202 | Impact of atorvastatin loaded exosome as an anti-glioblastoma carrier to induce apoptosis of U87 cancer cells in 3D culture model |
| Q82719918 | Impact of biomarkers expression before and after portal vein embolization on recurrence after two-stage hepatectomy for colorectal liver metastases |
| Q54354615 | In vitro chemoresponse assay based on the intrinsic subtypes in breast cancer. |
| Q39564707 | Induction of retinoid X receptor activity and consequent upregulation of p21WAF1/CIP1 by indenoisoquinolines in MCF7 cells. |
| Q33830630 | Interferon gamma-induced human guanylate binding protein 1 inhibits mammary tumor growth in mice |
| Q39084378 | Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells |
| Q37586533 | Invasive lobular carcinoma of the breast: long-term prognostic value of Ki67 and histological grade, alone and in combination with estrogen receptor |
| Q38597055 | Inverse relationship between Ki67 and survival in early luminal breast cancer: confirmation in a multivariate analysis. |
| Q37559738 | Joint detection of multiple immunohistochemical indices and clinical significance in breast cancer |
| Q58698990 | Ki 67 assessment in breast cancer in an Egyptian population: a comparative study between manual assessment on optical microscopy and digital quantitative assessment |
| Q35620685 | Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score |
| Q40045274 | Ki-67 Expression in Breast Cancer Tissue Microarrays: Assessing Tumor Heterogeneity, Concordance With Full Section, and Scoring Methods |
| Q58690262 | Ki-67 Labeling Index in Primary Invasive Breast Cancer from Sudanese Patients: A Pilot Study |
| Q80534301 | Ki-67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other |
| Q37705395 | Ki-67 as a predictor of response to neoadjuvant chemotherapy in breast cancer patients |
| Q36244265 | Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer |
| Q36609527 | Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients |
| Q35913434 | Ki-67 biomarker in breast cancer of Indian women |
| Q35558914 | Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis |
| Q38397819 | Ki-67 evaluation at the hottest spot predicts clinical outcome of patients with hormone receptor-positive/HER2-negative breast cancer treated with adjuvant tamoxifen monotherapy. |
| Q34003699 | Ki-67 is a prognostic biomarker of survival after radiofrequency ablation of liver malignancies |
| Q37245861 | Ki-67 is a prognostic marker for hormone receptor positive tumors. |
| Q36892788 | Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry |
| Q35111804 | Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis |
| Q36905903 | Ki-67 is required for maintenance of cancer stem cells but not cell proliferation. |
| Q34677862 | Ki-67 labeling in canine perianal glands neoplasms: a novel approach for immunohistological diagnostic and prognostic |
| Q49486164 | Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer: A meta-analysis |
| Q90836127 | Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study |
| Q34127775 | Ki-67 staining for determination of rhesus macaque T cell proliferative responses ex vivo |
| Q35904441 | Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review |
| Q53351065 | Ki67 Heterogeneity in Estrogen Receptor-Positive Breast Cancers: Which Tumor Type Has the Most Heterogeneity? |
| Q47156241 | Ki67 Proliferation Index as a Histopathological Predictive and Prognostic Parameter of Oral Mucosal Melanoma in Patients without Distant Metastases |
| Q38084286 | Ki67 and proliferation in breast cancer |
| Q33843751 | Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections |
| Q90236184 | Ki67 index in intrinsic breast cancer subtypes and its association with prognostic parameters |
| Q47719898 | Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. |
| Q33984087 | Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies |
| Q37096479 | Ki67-BCL2 index in prognosis of malignant peritoneal mesothelioma |
| Q33932379 | Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplasia |
| Q35145443 | LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer |
| Q37536186 | Localization and Molecular Characterization of human Breast Cancer Initiating Cells from heterogeneous population of Breast Cancer Mesenchymal Stem cells by Immunofluorescence Microscopy |
| Q101353570 | Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial |
| Q37683512 | Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer. |
| Q92509640 | Machine learning-based prediction of breast cancer growth rate in vivo |
| Q35806203 | Macroscopic optical physiological parameters correlate with microscopic proliferation and vessel area breast cancer signatures. |
| Q55107312 | Mammary fibroblasts reduce apoptosis and speed estrogen-induced hyperplasia in an organotypic MCF7-derived duct model. |
| Q37371417 | Mammary gland and endometrial effects of testosterone in combination with oral estradiol and progesterone |
| Q46944561 | Mammary gland development in early pubertal female macaques |
| Q35155460 | Management options in triple-negative breast cancer |
| Q53472937 | Menstrual cycle could affect Ki67 expression in estrogen receptor-positive breast cancer patients. |
| Q31134354 | Meroxest improves the prognosis of immunocompetent C57BL/6 mice with allografts of E0771 mouse breast tumor cells |
| Q61810938 | MicroRNA-204 inhibits the proliferation, migration and invasion of human lung cancer cells by targeting PCNA-1 and inhibits tumor growth in vivo |
| Q36457054 | Molecular biology of breast cancer |
| Q37765470 | Molecular circuits of solid tumors: prognostic and predictive tools for bedside use. |
| Q35676504 | Molecular drivers of lobular carcinoma in situ |
| Q35906338 | Molecular response to aromatase inhibitor treatment in primary breast cancer |
| Q33692020 | Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue |
| Q33616956 | Molecular sentinel-on-chip for SERS-based biosensing |
| Q33616968 | Multiplex detection of breast cancer biomarkers using plasmonic molecular sentinel nanoprobes |
| Q39299810 | Neoadjuvant Trials in ER+ Breast Cancer: A Tool for Acceleration of Drug Development and Discovery |
| Q33905507 | Netrin-1 promotes glioma growth by activating NF-κB via UNC5A |
| Q43733105 | Non-nuclear localization of Ki-67 in human colorectal cancer cells grown as multicellular layers |
| Q37620138 | Nox1 causes ileocolitis in mice deficient in glutathione peroxidase-1 and -2. |
| Q28247712 | Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer |
| Q41120614 | Nuclear grade plus proliferation grading system for invasive ductal carcinoma of the breast: validation in a tertiary referral hospital cohort |
| Q53455292 | Oil mixes omega 9, 6 and 3, enriched with seaweed, promoted reduction of thermal burned modulating NF-kB and Ki-67. |
| Q92757615 | On-treatment biomarkers can improve prediction of response to neoadjuvant chemotherapy in breast cancer |
| Q33698446 | Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment |
| Q36916152 | Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics |
| Q36026090 | Ovarian clear cell adenocarcinoma: a continuing enigma |
| Q30525568 | Overexpression of EVI1 interferes with cytokinesis and leads to accumulation of cells with supernumerary centrosomes in G0/1 phase. |
| Q39007103 | Peptide dendrimer-Doxorubicin conjugate-based nanoparticles as an enzyme-responsive drug delivery system for cancer therapy |
| Q35662698 | Physiologic and molecular changes in the tracheal epithelium of rats following burn injury. |
| Q53231153 | Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I. |
| Q37218912 | Potential biomarkers in the sera of breast cancer patients from bahawalpur, pakistan. |
| Q59812268 | Potential clinically useful prognostic biomarkers in triple-negative breast cancer: preliminary results of a retrospective analysis |
| Q38930073 | Potential nephroprotective effects of the Chinese herb Angelica sinensis against cisplatin tubulotoxicity |
| Q39740593 | Prediction of alternative isoforms from exon expression levels in RNA-Seq experiments |
| Q41345524 | Predictive factors of pathologic complete response in HER2-positive and axillary lymph node positive breast cancer after neoadjuvant paclitaxel, carboplatin plus with trastuzumab |
| Q35659702 | Preoperative Prediction of Ki-67 Labeling Index By Three-dimensional CT Image Parameters for Differential Diagnosis Of Ground-Glass Opacity (GGO). |
| Q55130351 | Prognostic Significance of Reduction in Ki67 Index After Neoadjuvant Chemotherapy in Patients With Breast Cancer in Kerman Between 2009 And 2014. |
| Q50457473 | Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer. |
| Q37327661 | Prognostic and predictive value of Ki-67 in triple-negative breast cancer |
| Q47104704 | Prognostic significance of lymphatic vessel invasion diagnosed by D2-40 in Chinese invasive breast cancers |
| Q36030405 | Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study |
| Q88404898 | Prognostic value of Ki-67 according to age in patients with triple-negative breast cancer |
| Q37548507 | Prognostic value of Ki-67 in breast cancer patients with positive axillary lymph nodes: a retrospective cohort study |
| Q88450978 | Prognostic value of Ki-67 index in adult medulloblastoma after accounting for molecular subgroup: a retrospective clinical and molecular analysis |
| Q54519817 | Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer. |
| Q37350137 | Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups |
| Q51122740 | Prognostic value of ki-67 in breast carcinoma: tissue microarray method versus whole section analysis- potentials and pitfalls. |
| Q43692538 | Prognostic value of proliferation markers expression in breast cancer |
| Q36316597 | Prognostic value of proliferation markers: immunohistochemical ki-67 expression and cytometric s-phase fraction of women with breast cancer in libya |
| Q35832458 | Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study |
| Q36393198 | Progranulin (GP88) tumor tissue expression is associated with increased risk of recurrence in breast cancer patients diagnosed with estrogen receptor positive invasive ductal carcinoma |
| Q34190743 | Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer. |
| Q39071852 | Protective effects of schizandrin and schizandrin B towards cisplatin nephrotoxicity in vitro |
| Q35889568 | Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial |
| Q24297639 | Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents |
| Q44966169 | Quantitative assessment Ki-67 score for prediction of response to neoadjuvant chemotherapy in breast cancer |
| Q91586076 | Quantitative assessment of Ki67 expression in correlation with various breast cancer characteristics and survival rate; cross sectional study |
| Q38848246 | Quantitative parameters of contrast-enhanced ultrasound in breast invasive ductal carcinoma: The correlation with pathological prognostic factors |
| Q34075234 | RNA helicase DDX5 regulates microRNA expression and contributes to cytoskeletal reorganization in basal breast cancer cells |
| Q35871716 | Rapid Alterations in Perirenal Adipose Tissue Transcriptomic Networks with Cessation of Voluntary Running |
| Q64284818 | Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant |
| Q34167327 | Recent advances in managing triple-negative breast cancers |
| Q38734599 | Reciprocal androgen receptor/interleukin-6 crosstalk drives oesophageal carcinoma progression and contributes to patient prognosis |
| Q34203765 | Reduction in Ki-67 in benign breast tissue of high-risk women with the lignan secoisolariciresinol diglycoside |
| Q39629474 | Reexpression of ARHI inhibits tumor growth and angiogenesis and impairs the mTOR/VEGF pathway in hepatocellular carcinoma |
| Q37638649 | Regional differences in breast cancer biomarkers in american Indian and Alaska native women |
| Q39599545 | Regulation of CD1, Ki-67, PCNA mRNA expression, and Akt activation in estrogen-responsive human breast adenocarcinoma cell line, MCF-7 cells, by griffonianone C, an isoflavone derived from Millettia griffoniana |
| Q93146161 | Relationship between 18-FDG-PET/CT and Clinicopathological Features and Pathological Responses in Patients with Locally Advanced Breast Cancers |
| Q46558451 | Relative and disease-free survival for breast cancer in relation to subtype: a population-based study |
| Q34795754 | Response prediction to neoadjuvant chemotherapy: comparison between pre-therapeutic gene expression profiles and in vitro chemosensitivity assay |
| Q37351061 | Restoration and reversible expansion of the osteoblastic hematopoietic stem cell niche after marrow radioablation. |
| Q36851857 | Reversal of multidrug resistance by cisplatin-loaded magnetic Fe3O4 nanoparticles in A549/DDP lung cancer cells in vitro and in vivo |
| Q36738790 | Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon? |
| Q33728161 | Salicylate •Phenanthroline copper (II) complex induces apoptosis in triple-negative breast cancer cells |
| Q30938639 | Scientific and Regulatory Policy Committee (SRPC) Review: Interpretation and Use of Cell Proliferation Data in Cancer Risk Assessment |
| Q37388652 | Semi-automated evaluation of Ki-67 index in invasive ductal carcinoma of the breast |
| Q45788491 | Short-term presurgical treatment for all? |
| Q38778088 | Single-Cell Characterization of 18F-FLT Uptake with Radioluminescence Microscopy. |
| Q36744585 | Soy isoflavones, estrogen therapy, and breast cancer risk: analysis and commentary |
| Q37345813 | St Gallen molecular subtypes in screening-detected and symptomatic breast cancer in a prospective cohort with long-term follow-up |
| Q42972655 | Stratifying triple-negative breast cancer: which definition(s) to use? |
| Q55228768 | Stromal immunoglobulin κC expression is associated with initiation of breast cancer in TA2 mice and human breast cancer. |
| Q36715181 | Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer |
| Q37560772 | Survivin, Ki-67 and tumor grade as predictors of response to docetaxel-based neoadjuvant chemotherapy in locally advanced breast cancer |
| Q38907787 | TRAF4 enhances osteosarcoma cell proliferation and invasion by Akt signaling pathway |
| Q36889682 | Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotype |
| Q39000880 | Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models |
| Q92402394 | The ENETS/WHO grading system for neuroendocrine neoplasms of the gastroenteropancreatic system: a review of the current state, limitations and proposals for modifications |
| Q36918165 | The Proliferative Activity of Mammary Epithelial Cells in Normal Tissue Predicts Breast Cancer Risk in Premenopausal Women |
| Q36732425 | The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naïve women with N0/N1 primary breast cancer |
| Q34587326 | The glomerular parietal epithelial cell's responses are influenced by SM22 alpha levels |
| Q44134114 | The impact of Girdin expression on recurrence-free survival in patients with luminal-type breast cancer |
| Q64998018 | The impact of Ki-67 in the context of multidisciplinary care in primary inflammatory breast cancer. |
| Q46324717 | The levels of Ki-67 positive are positively associated with lymph node metastasis in invasive ductal breast cancer |
| Q33575622 | The marine-derived sipholenol A-4-O-3',4'-dichlorobenzoate inhibits breast cancer growth and motility in vitro and in vivo through the suppression of Brk and FAK signaling |
| Q37045065 | The oestrogen-dependent biology of breast cancer. Sensitivity and resistance to aromatase inhibitors revisited: a molecular perspective |
| Q35037251 | The potential of hypoxia markers as target for breast molecular imaging--a systematic review and meta-analysis of human marker expression |
| Q44971609 | The potential utility of geminin as a predictive biomarker in breast cancer |
| Q92714480 | The prognostic significance of FBXO2 expression in colorectal cancer |
| Q46842412 | The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer |
| Q84946928 | The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer |
| Q34303247 | The role of TGFBI in mesothelioma and breast cancer: association with tumor suppression |
| Q45802829 | The role of tumor hypoxia in MUC1-positive breast carcinomas |
| Q40148453 | The use of digital images improves reproducibility of the ki-67 labeling index as a proliferation marker in breast cancer. |
| Q38972300 | Time-resolved dissection of early phosphoproteome and ensuing proteome changes in response to TGF-β. |
| Q35934478 | Trastuzumab and docetaxel in a preclinical organotypic breast cancer model using tissue slices from mammary fat pad: Translational relevance. |
| Q38397572 | Treatment response to preoperative anthracycline-based chemotherapy in locally advanced breast cancer: the relevance of proliferation and apoptosis rates |
| Q35740145 | Treatment-induced cell cycle kinetics dictate tumor response to chemotherapy |
| Q36747692 | Triple-negative breast cancer: therapeutic options |
| Q38407471 | Tumor RNA disruption predicts survival benefit from breast cancer chemotherapy |
| Q38873275 | Tumor apparent diffusion coefficient as an imaging biomarker to predict tumor aggressiveness in patients with estrogen-receptor-positive breast cancer |
| Q54405768 | Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patients. |
| Q34447829 | Tumor-infiltrating CD8+ and FOXP3+ lymphocytes in triple-negative breast cancer: its correlation with pathological complete response to neoadjuvant chemotherapy |
| Q30652903 | Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role. |
| Q37502362 | Tuning Hydrogel Properties to Promote the Assembly of Salivary Gland Spheroids in 3D. |
| Q35752791 | Unmanipulated native fat exposed to high-energy diet, but not autologous grafted fat by itself, may lead to overexpression of Ki67 and PAI-1. |
| Q37701617 | Use of non-selective β-blockers is associated with decreased tumor proliferative indices in early stage breast cancer |
| Q43549877 | Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer |
| Q37101590 | Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin |
| Q36012992 | What is the Prognostic Significance of Ki-67 Positivity in Oral Squamous Cell Carcinoma? |
| Q53084720 | Whey peptides prevent chronic ultraviolet B radiation-induced skin aging in melanin-possessing male hairless mice. |
| Q33555522 | Who would have thought a single Ki67 measurement would predict long-term outcome? |
| Q35666419 | Wnt2 promotes non-small cell lung cancer progression by activating WNT/β-catenin pathway |
| Q92282982 | ki67 nuclei detection and ki67-index estimation: a novel automatic approach based on human vision modeling |
| Q38007148 | mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions. |
| Q92581774 | miR‑381 functions as a tumor suppressor by targeting ETS1 in pancreatic cancer |
| Q33601161 | Δ(9)-Tetrahydrocannabinol disrupts estrogen-signaling through up-regulation of estrogen receptor β (ERβ) |
Search more.